Cambium Bio: Funding, Investors & Team (Sep 2026)
Cambium Medical Technologies, founded by four blood industry luminaries out of Emory University, Atlanta, Georgia (USA)--is focused on the development and commercialization of regenerative therapies derived from novel processed human platelets. Cambium is developing Elate Ocular a standardized, commercialized platelet derived biologic eye drop for dry eye syndrome (keratoconjunctivis sicca) as its first FDA approved therapy. Elate Ocular is an investigational drug and is not yet approved for sale in or outside the United States.
Cambium Bio has raised $1.9M across 1 funding round on record, the most recent an undisclosed round of $1.9M announced in Dec 2024.
That round is below the $4.7M median round size for Health Care companies tracked on FundedIQ over the last two years.
Cambium Bio Company Profile and Key Stats
Latest funding round on record: Dec 2024.
Cambium Bio Funding Rounds
Cambium Bio Founders and Leadership Team
No contact details are on record for this team yet.
Cambium Bio Funding Compared to Other Health Care Startups
Cambium Bio's latest round of $1.9M is below the median round in Health Care. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Cambium Bio in Health Care and Sydney
Companies Similar to Cambium Bio
Navi Medical Technologies is a company that specializes in the development of medical devices.
Adherium (previously known as Nexus6) is a privately owned developer and manufacturer of solutions that help…
Everlab is an Australian health-tech company building the infrastructure for preventative health
Sonder is the trusted wellbeing partner for some of the world’s most innovative organisations as they…
EMVision Medical is developing a portable brain scanner for rapid, point of care, stroke diagnosis and…
Gelteq is a biotechnology company specializing in the formulation, development, and manufacturing of…
Mixed Martial Arts Group is a company that specializes in technology and concentrates on the worldwide combat…
4DMedical (formerly known as 4Dx) is a global medical technology company aiming to change the outcome for…
Splose is delightful software for Allied Health Practitioners & NDIS Providers - The smarter way to support…
GenAqua Australia develops point-of-use water disinfection technology using high-strength UVC LED light to…
In 2013, Saluda Medical was founded with the objective of transforming four years of investigation from…
iiShield's goal is to enhance patient results and surgeon education in transplant surgery through the…
Cambium Bio Funding FAQs
What does Cambium Bio do?
Cambium Medical Technologies, founded by four blood industry luminaries out of Emory University, Atlanta, Georgia (USA)--is focused on the development and commercialization of regenerative therapies derived from novel processed human platelets. Cambium is developing Elate Ocular a standardized, commercialized platelet derived biologic eye drop for dry eye syndrome (keratoconjunctivis sicca) as its first FDA approved therapy. Elate Ocular is an investigational drug and is not yet approved for sale in or outside the United States.
How much funding has Cambium Bio raised?
Cambium Bio has raised $1.9M across 1 round on record. The most recent is an undisclosed round of $1.9M announced in Dec 2024.
When did Cambium Bio last raise funding?
Cambium Bio's most recent funding round on record is an undisclosed round of $1.9M, announced in Dec 2024.
Who founded Cambium Bio?
FundedIQ lists Jacques Galipeau (Founder) at Cambium Bio.
Where is Cambium Bio headquartered?
Cambium Bio is based in Sydney, New South Wales, Australia.
How many employees does Cambium Bio have?
Cambium Bio is in the 11-50 employee band.
How does Cambium Bio's funding compare to other Health Care startups?
Cambium Bio's latest round of $1.9M is below the $4.7M median round size for Health Care companies on FundedIQ across 3,653 tracked companies over the last two years.
About FundedIQ's Cambium Bio Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Cambium Bio is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.